Latest on Pharmaceutical Industry


Merck to buy virus-based cancer drug firm Viralytics for $394 million

U.S. drugmaker Merck & Co, already one of the leaders in the hot area of cancer immunotherapy, said on Wednesday it had agreed to buy Viralytics (VLA.AX) for 502 million Australian dollars ($394 million) to expand its pi..Read More...

Novo Nordisk gets nod from U.S. drug purchaser for new diabetes hope

Insulin maker Novo Nordisk said its Ozempic diabetes drug had been included on a list of medicines approved for patients covered by U.S. private health schemes, setting the stage for a battle with Eli Lilly’s Trulicity..Read More...



4th [Hospital + Innovation] Expo

INTEX Osaka,
Reed Exhibitions Japan Ltd.



INTEX Osaka,
Reed Exhibitions Japan Ltd.

Press Releases

Amneal Introduces Memantine Hydrochloride Extended-Release Capsules, Generic for Namenda XR®

Amneal Pharmaceuticals has launched memantine hydrochloride extendedrelease capsules the company39s ABrated equivalent for Namenda XR in 7 mg 14 mg 21 mg and 28 mg strengths The product is manufactured here in the United.. Read More...

5th Biennial Biosimilars & Biobetters Congress

With only a few months to go until our 5th Biennial Biosimilars Biobetters Congress we would like to present the latest agenda of this unmissable event On day 1 you will gain an insight into the recent updates in cli.. Read More...

Suppliers of the Month

Product Launch



Latest Reports


Latest Projects


Expert Talk

Bayer Pharmaceuticals

Bayer Pharmaceuticals Christoph Huwe PhD CAAM is a Strategic Alliance Manager Therapeutics at Bayer AG Pharmaceuticals with a focus on the BayerEvotec Endometriosis BayerEvotec Kidney Diseases BayerOncoMed Oncology strategic alliances and the Tuberculosis Drug Accelerator consortium He is also a member of Bayers Alliance. Read More...
Christoph Huwe
Strategic Alliance Manager Therapeutics